MLTX Overview

MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

Wall Street analysts forecast MLTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLTX is24.10 USD with a low forecast of 5.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

MoonLake Immunotherapeutics revenue for the last quarter amounts to -65.22M USD, increased 31.54

MoonLake Immunotherapeutics. EPS for the last quarter amounts to -58794000.00 USD, increased 20.85

MoonLake Immunotherapeutics (MLTX) has 130 emplpoyees as of March 25 2026.

Today MLTX has the market capitalization of 1.20B USD.